Henry Schein (NASDAQ:HSIC) Sets New 1-Year High on Strong Earnings

Henry Schein, Inc. (NASDAQ:HSIC)’s stock price hit a new 52-week high on Tuesday following a stronger than expected earnings report. The company traded as high as $89.29 and last traded at $87.6710, with a volume of 744143 shares. The stock had previously closed at $80.57.

The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.During the same quarter in the previous year, the firm earned $1.19 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 EPS and revenue beat — Henry Schein reported $1.34 EPS vs. $1.30 consensus and revenue up ~7.7% year‑over‑year, driven by strength in dental and medical equipment. This beat supports near‑term earnings momentum. Reuters: Henry Schein beats quarterly profit estimates
• Positive Sentiment: Revenue guidance raised above consensus — Management gave revenue guidance of roughly $13.6–$13.8 billion, modestly above consensus, signaling confidence in demand recovery for equipment and specialty offerings. Press Release / Slide Deck
• Positive Sentiment: Analyst upgrade — Robert W. Baird upgraded HSIC to “outperform” and raised its price target to $100, which likely attracted buyers and validated the recovery story. MSN: Baird upgrades Henry Schein
• Neutral Sentiment: FY‑2026 EPS guidance largely in line — Management provided an EPS range of 5.230–5.370 vs. consensus ~5.28, so guidance neither materially disappoints nor exceeds expectations; the company reiterated its outlook alongside the results. Press Release / Slide Deck
• Neutral Sentiment: Investor materials and call available — Management released a press deck and held a conference call (useful for detail on equipment demand and margin outlook). MarketBeat: Listen to Conference Call
• Negative Sentiment: Margin contraction — Gross and operating margins declined, tempering the beat and suggesting cost or product‑mix pressures even as equipment and specialty sales recover; margin trends will be watched closely in coming quarters. Zacks: HSIC Q4 earnings & revenues beat; margins down

Analysts Set New Price Targets

A number of brokerages recently commented on HSIC. Barrington Research set a $79.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Barclays started coverage on Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price on the stock. Mizuho set a $81.00 price objective on shares of Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $78.75.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently modified their holdings of the company. MAI Capital Management lifted its stake in shares of Henry Schein by 7.5% in the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after purchasing an additional 144 shares during the last quarter. CW Advisors LLC grew its stake in shares of Henry Schein by 2.8% in the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after acquiring an additional 163 shares in the last quarter. Truist Financial Corp increased its position in shares of Henry Schein by 3.3% during the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after acquiring an additional 175 shares during the period. Simon Quick Advisors LLC raised its stake in shares of Henry Schein by 5.5% in the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock valued at $253,000 after acquiring an additional 182 shares in the last quarter. Finally, Claret Asset Management Corp increased its stake in shares of Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after buying an additional 187 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

The company has a market capitalization of $10.19 billion, a PE ratio of 27.46, a P/E/G ratio of 2.37 and a beta of 0.88. The stock’s 50-day simple moving average is $77.43 and its 200 day simple moving average is $71.78. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.